SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001047469-16-016388
Filing Date
2016-10-31
Accepted
2016-10-28 20:08:45
Documents
11

Document Format Files

Seq Description Document Type Size
1 424B5 a2230099z424b5.htm 424B5 967510
2 G446477.JPG g446477.jpg GRAPHIC 19756
3 G756043.JPG g756043.jpg GRAPHIC 147669
4 G549205.JPG g549205.jpg GRAPHIC 127470
5 G756313.JPG g756313.jpg GRAPHIC 3121
6 G154603.JPG g154603.jpg GRAPHIC 3908
7 G364648.JPG g364648.jpg GRAPHIC 3921
8 G339009.JPG g339009.jpg GRAPHIC 4156
9 G190402.JPG g190402.jpg GRAPHIC 3678
10 G351405.JPG g351405.jpg GRAPHIC 5525
11 G7385.JPG g7385.jpg GRAPHIC 25754
  Complete submission text file 0001047469-16-016388.txt   1445062
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-214257 | Film No.: 161959805
SIC: 2834 Pharmaceutical Preparations